Loading company…
PeLeMed researches and develops drugs for cancer, neurological and immune diseases.
Founded in 2019 and based in Gwangju, South Korea, PeLeMed develops drugs for cancer, neurological and immune diseases. It raised KRW 5 billion in venture funding in September 2026 to advance its acute myeloid leukemia candidate PLM-102, including a U.S. Phase I trial, and develop other oncology programs.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in